PBAC's latest decision on Varenicline: Recommended (2017). Considered for Nicotine dependence; continuation of a short-term course of treatment (12 weeks or up to 24 weeks) as an aid to achieving abstinence from smoking.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
4
first 2012
Submissions
4
2012 → 2017
Eligible population
Patients with nicotine dependence requiring continuation of a short-term course of treatment (12 weeks or up to 24 weeks), including those who received an initiation pack as an inpatient in a public hospital.
Therapy area
Mental health
Line of therapy
Not applicable
Economic model
Not modelled
ICER note
This was a minor submission; no economic evaluation or ICER calculated.
ICER (historical)
$15k/QALY in an earlier submission (2014) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Nov 2012: Not recommended
Mar 2014: Recommended with restriction · Authority Required — ICER $15k/QALY
Nov 2016: Recommended with restriction · Authority Required